Impact of Global Education on Decision-Making Related to Disease Modifying Therapy in Multiple Sclerosis (P3.237)

CONCLUSIONS: Significant improvements were observed on knowledge, competence, and performance of US and OUS neurologists regarding decisions about new DMTs in MS as a result of participation in the CME activity. Study Supported by: Biogen IdecDisclosure: Dr. Schaumburg has nothing to disclose. Dr. Krieger has received personal compensation for activities with Acorda Therapeutics, Bayer HealthCare, Biogen Idec, EMD Serono, Genzyme, Questcor Pharmaceuticals, and Teva Neuroscience as a consultant and/or advisory board member.

Source: Neurology - April 8, 2015 Category: Neurology Authors: Schaumburg, R., Krieger, S. Tags: MS and CNS Inflammatory Diseases: Tools for Clinical Assessment and Therapeutic Response Source Type: research